HDAC6 and Parkinson disease: Tubastatin A, as an HDAC6 inhibitor, was shown to protect dopaminergic neurons in a rat model of PD through the reduction in the α-synuclein level and neuroinflammation, the promotion of chaperone-mediated autophagy, and the elimination of other PD-related pathological pathways [114,115].